ArticlemBio2025
Carrier-mediated transport as a common route of antibiotic ingress into bacteria.
Article in mBio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Reversing Antibiotic Resistance: Strategies From Adjuvants to Innovative Therapeutics.MicrobiologyOpen · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Among the most significant challenges in antibacterial discovery is achieving delivery of small molecule inhibitors across the bacterial membrane(s) to reach their intracellular targets. It is considered axiomatic that the typical route for antibiotics across the cytoplasmic membrane (CM) involves diffusion directly through the lipid bilayer, though this concept has not translated into actionable information for rationally achieving ingress of inhibitors into bacteria. Here, using antibiotic accumulation measurements in bacteria inactivated for individual or multiple CM transporters, we provide evidence that a diverse range of established antibiotic classes are transported across the CM by hitch-hiking on carrier proteins. The chemical similarity between some antibiotic classes and the native substrate(s) of the importer they share provides a molecular logic for drug transport. Our results indicate that carrier-mediated uptake is a common route of antibiotic entry into bacteria and highlight the value of metabolite mimicry in designing new antibacterial drugs. IMPORTANCE: Increasing antibiotic resistance among pathogenic bacteria is undermining our ability to treat infection, and new antibacterial drugs are urgently needed to address the problem. One of the most significant challenges in antibacterial discovery is achieving delivery of inhibitors across the bacterial membrane(s) to reach their intracellular targets, reflecting the lack of a granular understanding about how antibiotics enter bacteria. Here, we provide evidence that a common route for established antibiotics into bacteria involves uptake by membrane transport proteins. Our findings thereby offer a clear route forward for antibacterial discovery: mimicry of the natural substrates of transporter proteins to achieve carrier-mediated uptake of inhibitors into the bacterial cell.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.